PROfound Trial: OS Improvement With Olaparib in Subset of Patients With mCRPC

Published by W Butcher on

In men with metastatic castration-resistant prostate cancer (mCRPC) and mutations in genes associated with homologous recombination repair (HRR), such as BRCA1 or BRCA2, olaparib improves overall survival (OS), according to results of the open-label, phase 3 PROfound trial.

Read More…

Categories: Uncategorized